Demographic and clinical backgrounds of the patients with RA, and the HD.
| Patient | Age, yrs | Sex | SE Dosage | DAS28-CRP | Anti-CCP Ab, U/ml | Medication | Cytokine Assay |
|---|---|---|---|---|---|---|---|
| RA | |||||||
| 1 | 65 | M | 1 | 2.23 | 1770 | PSL 3 mg, ABA, 750 mg/m | Available |
| 2 | 55 | M | 2 | 1.83 | 218 | No medication | Available |
| 3 | 75 | M | 1 | 3.92 | 246 | PSL 8 mg | Available |
| 4 | 44 | F | 0 | 1.76 | 27 | No medication | Available |
| 5 | 54 | F | 0 | 1.15 | 47 | MTX 10 mg/wk | Available |
| 6 | 48 | F | 0 | 4.16 | 0 | No medication | Available |
| 7 | 31 | F | 1 | 1.18 | 399 | MTX 10 mg/wk | Available |
| 8 | 73 | F | 1 | 3.37 | 327 | MTX 4 mg/wk, PSL 5 mg | Available |
| 9 | 74 | F | 1 | 4.20 | 500 | No medication | Available |
| 10 | 52 | M | 1 | 5.21 | 18 | No medication | Available |
| 11 | 46 | F | 0 | 4.18 | 154 | PSL 16 mg, IVCYC | Available |
| 12 | 42 | F | 2 | 3.84 | 11 | MTX 8 mg/wk, PSL 5 mg | Available |
| 13 | 77 | F | 2 | 4.76 | 79 | PSL 10 mg | Available |
| 14 | 73 | F | 1 | 4.05 | 8 | MTX 12 mg/wk, PSL 4.5 mg | Available |
| 15 | 58 | M | 0 | 3.35 | 403 | PSL 6 mg | Available |
| 16 | 66 | M | 1 | 3.41 | 500 | MTX 10 mg/wk, TCZ | Available |
| 17 | 53 | F | 0 | 2.60 | 3 | PSL 3 mg, ABA | Available |
| 18 | 56 | F | 0 | 3.21 | 1 | PSL 5 mg | Available |
| 19 | 64 | F | 1 | 2.72 | 15 | PSL 1.5 mg, Tofa 10 mg | No |
| 20 | 75 | F | 2 | 5.44 | 0 | PSL 5 mg, Tofa 5 mg | No |
| 21 | 53 | F | 2 | 6.22 | 20 | MTX 6 mg/wk, PSL 5 mg, Tofa 10 mg | No |
| 22 | 62 | F | 1 | 4.28 | 16 | MTX 6 mg/wk, Tofa 10 mg | No |
| HD | |||||||
| 1 | 45 | F | 0 | ||||
| 2 | 44 | F | 0 | ||||
| 3 | 53 | F | 0 | ||||
| 4 | 53 | F | 0 | ||||
| 5 | 56 | F | 0 | ||||
| 6 | 71 | F | 0 | ||||
| 7 | 55 | F | 0 | ||||
| 8 | 71 | F | 1 | ||||
| 9 | 50 | F | 0 | ||||
| 10 | 52 | F | 0 | ||||
| 11 | 57 | F | 0 | ||||
| 12 | 52 | F | 1 | ||||
| 13 | 47 | F | 0 | ||||
| 14 | 48 | F | 1 | ||||
| 15 | 45 | M | 1 | ||||
| 16 | 52 | F | 0 | ||||
| 17 | 51 | F | 0 | ||||
| 18 | 57 | F | 0 |
RA: rheumatoid arthritis; HD: healthy donors; SE: shared epitope; MTX: methotrexate; PSL: prednisolone; ABA: abatacept; TCZ: tocilizumab; IVCYC: intravenous cyclophosphamide pulse therapy; Tofa: tofacitinib; DAS28-CRP: 28-joint count Disease Activity Score using C-reactive protein; anti-CCP: anticyclic citrullinated peptide; Ab: antibody.